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Immunoglobulin G 
in Ebola Outbreak 
Survivors, Gabon
To the Editor: Three well-docu-
mented outbreaks of Ebola hemorrhag-
ic fever occurred from 1996 through 
2001 in Gabon in central Africa (1). All 
were caused by the highly pathogenic 
species Zaire ebolavirus, which is asso-
ciated with an ≈80% case-fatality rate. 
The first outbreak hit Mayibout, a vil-
lage in northeast Gabon in January and 
February 1996, causing 31 cases and 
21 deaths. The first victims were chil-
dren who helped carry and butcher a 
chimpanzee carcass found in the forest. 
The second outbreak lasted from Octo-
ber 1996 through March 1997 and oc-
curred in the Booué region, about 150 
km  southwest  of  Mayibout,  Gabon. 
The outbreak area was located along 
a  trunk  road  and  railroad  track,  and 
the infection spread to several villages 
around Booué, then to Libreville, the 
capital of Gabon, where 15 cases were 
recorded. The third outbreak occurred 
October  2001  through  May  2002  in 
the Mekambo area, about 150 km from 
Mayibout  in  the  east  (2).  This  out-
break consisted of several independent 
chains of human transmission arising 
from infected animal carcasses, mainly 
chimpanzees and gorillas. It caused 65 
cases and 53 deaths and coincided with 
major outbreaks in great apes that deci-
mated wild populations (3,4). A total of 
207 human cases were recorded during 
these  3  outbreaks;  149  persons  died. 
Of the fatal and nonfatal cases 31 and 
24,  respectively,  were  confirmed  by 
real-time  reverse  transcription–PCR, 
antigen detection, and immunoglobulin 
(Ig) G ELISA at Centre International de 
Recherches  Médicales  de  Franceville 
(CIRMF) in Gabon.
Because  of  the  lack  of  avail-
able samples from survivors, little is 
known about the duration of IgG an-
tibody response. However, studies of 
20  survivors  convalescing  after  the 
1995 Kikwit outbreak in the Demo-
cratic Republic of the Congo (DRC) 
showed  that  Zaire  ebolavirus  IgG 
appeared 5 to 18 days after symptom 
onset and persisted at least 21 months 
(5,6). With the exception of 2 survi-
vors sampled 10 years after the 1976 
Yambuku  outbreak  in  DRC  (7),  no 
data are available on Zaire ebolavirus 
IgG  persistence  beyond  21  months. 
Low seroprevalence rates of Ebola vi-
rus or Marburg virus found in surveys 
of patients in outbreak areas have been 
attributed to seroreversion (8–10).
To  investigate  the  persistence 
of Zaire ebolavirus IgG, we studied 
laboratory-confirmed  survivors  of 
the 3 outbreaks in Gabon. The study 
was approved by the Gabon Ministry 
of Health and by the traditional chief 
of each village, and written informed 
consent was obtained from each survi-
vor. During 3 months of investigations 
in the different outbreak areas begin-
ning in June 2007, we located 11, 3, 
and 6 survivors of the 2001 Mekam-
bo, 1996 Booué, and 1996 Mayibout 
outbreaks, respectively. During home 
visits, the survivors underwent a brief 
medical consultation, malaria smears 
were taken, and basic medicines were 
provided to the villagers. We collected 
blood samples in EDTA tubes; plasma 
was separated by centrifugation in the 
field and stored in dry nitrogen until 
transfer to the CIRMF laboratory in 
Gabon, where it was stored at –80°C. 
ELISA was performed as previously 
described, using reagents provided by 
the  Special  Pathogens  Branch,  Cen-
ters for Disease Control and Preven-
tion (Atlanta, GA, USA) (7). The opti-
cal density (OD) cut-off value (0.13) 
was calculated as the mean + 3 SD of 
adjusted OD values for 103 negative 
control serum samples obtained from 
Caucasian persons living in Europe.
All  20  survivors  had  positive 
test results for Zaire ebolavirus IgG 
(Table). The adjusted OD values at a 
dilution  of  1:1,600  ranged  from  0.3 
to 3.4 in the 9 survivors of the 1996 
outbreaks and from 0.7 to 3.5 in the 
11 survivors of the 2001 outbreak. Ad-
justed OD values determined during 
the symptomatic period and/or a few 
days to 1 month after recovery were 
available for some survivors (Table). 
Specific IgG appeared by day 5 after 
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Table.	Adjusted	OD	values	in	patients	infected	with	Zaire ebolavirus	during	3	outbreaks	
in	Gabon,	determined	by	testing	at	days	5,	10,	and/or	30	after	symptom	onset	and	
again	in	2007	(7	or	11	years	after	recovery)*	
Adjusted	OD	at	1:1,600	dilution	 Patient
no.
Outbreak	location	
and	year	 Day	5	 Day	10	 Day	30	 2007
1 Mayibout	1996	 0.05 1.50 2.52 1.41
2 Mayibout	1996	 0.44 0.58 1.14 0.30
3 Mayibout	1996	 0.22 1.90 3.17
4 Mayibout	1996	 2.09
5 Mayibout	1996	 2.31 0.65
6 Mayibout	1996	 1.11 3.46
7 Booué	1996	 2.64 0.71
8 Booué	1996	 1.56 0.49
9 Booué	1996	 1.26 1.55 0.31
10 Mekambo	2001	 2.60
11 Mekambo	2001	 1.90 1.46
12 Mekambo	2001	 2.05 0.84
13 Mekambo	2001	 0.80 2.13
14 Mekambo	2001	 1.84
15 Mekambo	2001	 0.71
16 Mekambo	2001	 2.77
17 Mekambo	2001	 0.10 3.50
18 Mekambo	2001	 0.46 1.33
19 Mekambo	2001	 0.03 2.50
20 Mekambo	2001	 2.90 0.99
*Blank	cells	indicate	data	are	missing	or	testing	was	not	performed.	OD,	optical	density.	LETTERS
symptom onset, increased during the 
symptomatic  period  (as  shown  by 
higher titers on day 10), peaked by day 
30 (2 weeks after recovery), then de-
clined slowly over several years. Zaire 
ebolavirus  IgG  remained  detectable, 
often at high levels, >11 years after 
the infection.
These long-lasting IgG antibody 
responses found in 20 survivors of 3 
different  Zaire  ebolavirus  outbreaks 
rule out the hypothesis that low Ebola 
virus (and Marburg virus) seropreva-
lence rates found in epidemic regions 
of Africa are due to rapid loss of spe-
cific  IgG. Whether  this  immunity  is 
sufficient to protect from recurrent in-
fection remains undetermined. These 
findings show that IgG ELISA is suit-
able for epidemiologic and epizootio-
logic investigations of Ebola and that 
Zaire ebolavirus IgG is an excellent 
indicator of Zaire ebolavirus circula-
tion in humans.
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Varibaculum  
cambriense  
Infections in Hong 
Kong, China, 2006 
To the Editor: Varibaculum cam-
briense  is  an  anaerobic,  gram-posi-
tive,  diphtheroid  bacterium  that  was 
described by Hall et al. in 2003 (1). 
Biochemical  testing,  electrophoretic 
analysis  of  whole-cell  proteins,  and 
phylogenetic  analysis  of  16S  rRNA 
gene sequences showed that V. cam-
briense is related to but distinct from 
Actinomyces  spp.  and  related  taxa, 
including the genera Actinobaculum, 
Arcanobacterium, and Mobiluncus.
Although  its  natural  habitat  re-
mains  unknown,  V.  cambriense  has 
been  isolated  from  intrauterine  de-
vices and human vagina and abscess 
specimens (2). Commercial systems, 
such as analytical profile index (API) 
Rapid  ID  32  Strep  and  Coryne  kits 
(bioMérieux, Marcy l’Etoile, France), 
used in differentiation of novel bacte-
ria provide biochemical profiles useful 
for identification of V. cambriense (1). 
However, the absence of data on this 
organism in manufacturers’ databases 
has hampered recognition of V. cam-
briense in routine clinical laboratories. 
We report 4 cases of V. cambriense in-
fection and show that this bacterium is 
a potential pathogen in skin and soft 
tissue infections.
In  2006,  four  isolates  of  gram-
positive  curved  bacilli  that  grew  on 
Columbia agar with 5% horse blood 
under  anaerobic  conditions  were  re-
ferred by 2 regional hospitals in Hong 
Kong to our laboratory for identifica-
tion.  These  isolates  originated  from 
the abscess specimens of 4 patients.
Patient 1 was a 45-year-old wom-
an with a right ovarian chocolate cyst 
and endometriosis who had undergone 
laparotomy, right salpingo-oophorec-
tomy, and lysis of adhesions in 2001. 
Since then, she had a recurrent abscess 
over the umbilical scar that was treat-
ed conservatively. Culture of pus from 
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